who and why dumping, page-62

There was ridciulous hype driving this stock & most posts here where feeding it as the whole thumb thing indicated. You have to remember lead candidate completes PhaseI & besides that very little cash in bank, when compared to the sector as a whole it was way outside of its ball park. Yes they have pre-clinical candidates but you also have to remember when valuing anything pre-clinical you really attribute nothing to value unless market is hyped on the potential in which case it should never exceed 1% - drugs in trials reduce associated risk as they succesfully progress hence PhaseI completed lifts the fair value rank to a 10% chance of succefully meeting the end point - but no cash is generated for many years so as opposed to valuing something on the potential cash return you are pricing against it against expenditure to get to the next stage.

Where it is now is probably fair at $25M although it is still higher than others at this point & really to justify they need cash in place.

All these $100M ball park figures where so bogus it was embarrasing the last few weeks but apparently everyone agreed that's where fair value laid & where ANP should be heading. Take time to look at the whole picture not just relying on other posters & what you/they want to see happen.